Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.


Journal

Cytokine & growth factor reviews
ISSN: 1879-0305
Titre abrégé: Cytokine Growth Factor Rev
Pays: England
ID NLM: 9612306

Informations de publication

Date de publication:
06 2021
Historique:
received: 01 02 2021
accepted: 09 02 2021
pubmed: 22 2 2021
medline: 29 9 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

During the Tenth Edition of the Annual Congress on "Anticancer Innovative Therapy" [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell-based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.

Identifiants

pubmed: 33610464
pii: S1359-6101(21)00017-4
doi: 10.1016/j.cytogfr.2021.02.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Subventions

Organisme : Cancer Research UK
ID : 23110
Pays : United Kingdom

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Francesca De Santis (F)

Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Giovanni Fucà (G)

Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Dirk Schadendorf (D)

Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.

Alberto Mantovani (A)

Istituto Clinico Humanitas IRCCS, Rozzano, Italy.

Luca Magnani (L)

Department of Surgery and Cancer, Imperial College London, London, UK.

Michael Lisanti (M)

Translational Medicine, School of Science, Engineering and Environment [SEE], Biomedical Research Centre [BRC], University of Salford, Greater Manchester, United Kingdom.

Stephen Pettitt (S)

The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.

Matteo Bellone (M)

Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.

Giannino Del Sal (G)

Department of Life Sciences, University of Trieste, 34127, Trieste, Italy.

Saverio Minucci (S)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Alexander Eggermont (A)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.

Paolo Bruzzi (P)

Unit of Clinical Epidemiology, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.

Silvio Bicciato (S)

Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Pierfranco Conte (P)

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Roberta Noberini (R)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

John Hiscott (J)

Laboratorio Pasteur, Istituto Pasteur-Fondazione Cenci-Bolognetti, 00161, Rome, Italy.

Filippo De Braud (F)

Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Michele Del Vecchio (M)

Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Massimo Di Nicola (M)

Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: massimo.dinicola@istitutotumori.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH